Korean J Psychopharmacol.  2007 Sep;18(5):318-328.

Risperidone Combination in the Acute Treatment of Bipolar Mania and Mixed Episode: Prospective, Multicenter, Open Trial

Affiliations
  • 1Department of Psychiatry, College of Medicine, The Catholic of University of Korea, Seoul, Korea. wmbahk@catholic.ac.kr
  • 2Department of Psychiatry, College of Medicine, Hallym University, Anyang, Korea.
  • 3Department of Psychiatry, Chonbuk National University Medical School, Jeonju, Korea.
  • 4Department of Neuropsychiatry, College of Medicine, Wonkwang University, Iksan, Korea.
  • 5Department of Psychiatry, Seoul National University Hospital, Seoul, Korea.
  • 6Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea.
  • 7Department of Psychiatry, Maryknoll Hospital, Busan, Korea.
  • 8Yong-In Mental Hospital, Yongin, Korea.
  • 9Department of Neuropsychiatry, College of Medicine, Chung-Ang University, Seoul, Korea.
  • 10Naju National Hospital, Naju, Korea.

Abstract


OBJECTIVE
Although mood stabilizer monotherapy is the recommended initial therapy for bipolar disorder, the use of atypical antipsychotics in bipolar patients is increasing recently. Moreover, the medical literature is demonstrating that the combination of atypical antipsychotics and mood stabilizers is a more effective therapy. The goal of this study was to assess the efficacy of risperidone in patients with acute manic and mixed state of bipolar disorder.
METHODS
This study was a 4-week, open-label, combination, prospective investigation using risperidone in combination with mood stabilizers. In total, 114 patients with a DSM-IV diagnosis of bipolar disorder, manic or mixed episode, were recruited. Risperidone was given in combination with mood stabilizers in doses according to clinical response and tolerability. Efficacy was assessed with the Young Mania Rating Scale (YMRS), the Hamilton Rating Scale for Depression (HAMD), the Brief Psychiatric Rating Scale (BPRS), Global Assessment Scale (GAS), and the Clinical Global Impressions Scale-Bipolar (CGI-BP). The Simpson-Angus Rating Scale (SARS) was applied to assess extrapyramidal symptoms.
RESULTS
The combination of risperidone with mood stabilizers produced highly significant improvements (p<0.001) on the YMRS, HAMD, BPRS, GAS, and CGI-BP at both 1 week and 4 weekweeks. Analysis of the YMRS, BPRS, GAS, and CGI-BP scores revealed significant improvement in both the manic and mixed group. The HAMD score was decreased only in the mixed group. Body weight was increased significantly after 1 week. Risperidone was well tolerated, and adverse events were mostly mild, with the most frequent extrapyramidal symptoms and sedation.
CONCLUSION
Our findings suggest that the combination of risperidone with mood stabilizers was an effective and safe treatment for acute manic symptoms and coexisting depressive symptoms of bipolar disorder. Randomized, double-blind, placebo or active controlled studies are needed.

Keyword

Risperidone; Mixed state; Bipolar disorder; Mood stabilizer

MeSH Terms

Antipsychotic Agents
Bipolar Disorder*
Body Weight
Brief Psychiatric Rating Scale
Depression
Diagnosis
Diagnostic and Statistical Manual of Mental Disorders
Humans
Prospective Studies*
Risperidone*
Antipsychotic Agents
Risperidone
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr